Allied Research International (ARI), a member of Cetero Research, has been in operation since 1989. As part of a family with 3 other clinical and bioanalytical companies (PRACS Institute, Gateway Medical Research, and Ba Research), we are one of the world's leading providers of early stage, bioanalytical and niche late stage clinical research services to the life sciences industry.
ARI was founded by Dr. Piyush Patel, CEO and Principal Scientist and Mrs. Arti Patel, President and Physician Network Manager. ARI's foundations were built from Dr. Patel's work as a principal investigator in allergy/asthma clinical research. In 1999, Paul Benninger, Chief Operations Officer at ARI, joined the company and opened a 76-bed clinical pharmacology unit with 12 employees. To support our early phase clinical services, ARI added a bioanalytical laboratory in 2002. Building on our success in single-center trial management, ARI expanded the repertoire of services in 2005 to include planning, managing and monitoring multi-center trials in Phases II through IV of the drug development process.
Combining his experience in clinical research and his specialization in allergy and clinical immunology, Dr. Patel refined the existing clinical models in allergy research and built ARI's first Environmental Exposure Chamber (EEC) in 2001. This 121-seat EEC is custom designed to conduct allergen exposure studies at any time of the year, independent of the traditional allergy seasons. With the success of the first EEC, ARI increased its R&D efforts in developing more clinical models and built its second EEC in 2004. Today, as part of Cetero Research, ARI continues to pursue scientific excellence. We are committed to research and development of the EEC technology. Our scientists are actively innovating clinical models for respiratory, immunology, and ophthalmic therapeutic areas.
The opening of the 137-bed clinical pharmacology unit in Miami, USA in spring 2006 marked ARI's growth into the US market. In fall of 2006, ARI established a Central Laboratory, completed with state-of-the-art instrumentation in support of our expanding clinical services.
ARI was acquired by Cetero Research on March 20, 2007. ARI is now part of a family of other clinical and bioanalytical research specialists. More than ever, ARI is focused and committed to research and scientific excellence.
Contact us today to find out how you can leverage on our experience and expertise to accelerate your drug development plan.
